Cardiotoxicity Epidemiology Forecast 2025-2034

The cardiotoxicity epidemiology forecast suggests that cardiotoxicity is common in adults who had cancer treatment as children. The exact rate of cardiotoxicity in adults who received cancer treatment as adults is not known, but some estimates suggest that up to 20% of these individuals may develop heart issues, and around 7% to 10% may experience cardiomyopathy or heart failure, according to the Cleveland Clinic. Further, a study published in the Cardiology Journal (2022) found that 16.5% of patients treated with low doses of anthracyclines developed long-term cardiotoxicity after 4.5 years.

Cardiotoxicity Epidemiology Forecast Report Coverage

The “Cardiotoxicity Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of cardiotoxicity. It projects the future incidence and prevalence rates of cardiotoxicity cases across various populations. The study covers age and type as major determinants of the cardiotoxicity population. The report highlights patterns in the prevalence of cardiotoxicity over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on cardiotoxicity epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Cardiotoxicity Understanding: Disease Overview

Cardiotoxicity refers to heart damage caused by certain cancer treatments. Chemotherapy drugs like anthracyclines, targeted therapies such as trastuzumab, and radiation therapy to the chest area can cause cardiotoxicity. The damage can range from mild, subclinical changes in heart function to severe heart failure, arrhythmias, or even sudden cardiac death. Acute cardiotoxicity occurs during or shortly after cancer treatment, presenting as arrhythmias or changes in heart function. On the other hand, chronic cardiotoxicity develops months or years after treatment, often leading to heart failure or cardiomyopathy. Studies show that pre-existing conditions like hypertension, diabetes, and obesity can increase the likelihood of cardiotoxicity.

Cardiotoxicity Epidemiology Perspective

The cardiotoxicity epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for cardiotoxicity epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The cardiotoxicity detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• A 2022 study published in the Cardiology Journal found that 16.5% of patients who received low doses of anthracyclines developed long-term cardiotoxicity at 4.5 years.
• The exact rate of cardiotoxicity in adults treated for cancer as an adult is unclear, but estimates suggest up to 20% may develop heart issues, with 7% to 10% likely to suffer from cardiomyopathy or heart failure, according to the Cleveland Clinic.
• A 2022 multicenter retrospective study found that 9.68% of 341 breast cancer patients treated with anthracycline-based chemotherapy developed cardiotoxicity. The study also found that patients with pre-existing comorbidities were 12 times more likely to develop anthracycline-induced cardiotoxicity.
• A large patient population study (2022) on anthracycline therapy for breast cancer estimated a 1.98-fold increased risk of cardiomyopathy or heart failure, and a 2.91-fold higher risk of mortality from cardiovascular events compared to matched controls.
• The occurrence of chemotherapy-induced cardiac disease in patients receiving only anthracyclines is estimated to range from 4% to 36%. Further, clinically evident cardiotoxicity occurs in 6%, while subclinical cardiotoxicity is observed in 18%, as per Srikanthan, Krithika, et al. (2017).

Country-wise Cardiotoxicity Epidemiology Segment

The cardiotoxicity epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of cardiotoxicity varies significantly between countries due to differences in factors such as healthcare access, treatment protocols, drug use, environmental exposures, lifestyle patterns, and the prevalence of cancer and pre-existing health conditions. According to the American Cancer Society (ACS), more than 2 million new cancer cases are expected to be diagnosed in the United States in 2025. This increasing cancer burden means that a larger population in the region will be exposed to treatments that can lead to cardiotoxicity.

Cardiotoxicity: Treatment Overview

Prophylactic medications (beta-blockers and ACE inhibitors) are cardiotoxicity therapeutics that may be prescribed to protect the heart during cancer treatment, especially for patients at higher risk. Angiotensin-converting enzyme (ACE) inhibitors are used to reduce blood pressure and decrease the strain on the heart. These drugs are helpful in managing heart failure caused by cardiotoxicity.

In some cases, aldosterone antagonists like spironolactone may be used to address heart failure symptoms. Additionally, advanced interventions are being increasingly explored, such as stem cell therapy and gene editing techniques, to repair damaged heart tissue and reverse some effects of cardiotoxicity.

Key Questions Answered

• What are the key findings of cardiotoxicity epidemiology in the 8 major markets?
• What will be the total number of patients with cardiotoxicity across the 8 major markets during the forecast period?
• What was the country-wise cardiotoxicity epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cardiotoxicity patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of cardiotoxicity during the forecast period of 2025-2034?
• What are the currently available treatments in the cardiotoxicity market?
• What are the disease risks, signs, symptoms, and unmet needs of cardiotoxicity?

Scope of the Cardiotoxicity Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cardiotoxicity based on several factors.
• The Cardiotoxicity Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The cardiotoxicity report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.